Section Arrow
EDIT.NASDAQ
- Editas Medicine
Quotes are at least 15-min delayed:2025/01/12 05:18 EST
Last
 1.26
-0.08 (-5.97%)
Day High 
1.34 
Prev. Close
1.34 
1-M High
2.23 
Volume 
2.54M 
Bid
1.26
Ask
1.28
Day Low
1.23 
Open
1.33 
1-M Low
1.1601 
Market Cap 
110.61M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.3 
20-SMA 1.43 
50-SMA 2.16 
52-W High 11.58 
52-W Low 1.1601 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.54/-2.22
Enterprise Value
134.99M
Balance Sheet
Book Value Per Share
2.13
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
78.12M
Operating Revenue Per Share
0.30
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CDTConduit Pharmaceuticals0.1233+0.0413+50.37%-- 
MRSNMersana Therapeutics0.72-0.58-44.62%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.2787+0.0227+8.87%-- 
ZVSAZyVersa Therapeutics1.47+0.29+24.58%0PE
SANASana Biotechnology3.66-0.64-14.88%-- 
Quotes are at least 15-min delayed:2025/01/12 05:18 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.